Information de reference pour ce titreAccession Number: | 00003033-201310000-00002.
|
Author: | Ameri, Pietro 1,2; Giusti, Andrea 3; Boschetti, Mara 4; Murialdo, Giovanni 2; Minuto, Francesco 4; Ferone, Diego 4
|
Institution: | (1)Division of Endocrinology, Department of Medicine, New York University School of Medicine, New York, NY, USA (2)Unit of Internal Medicine, Department of Internal Medicine and Medical Specialties, IRCCS-AOU San Martino-IST, University of Genova, Genova, Italy (3)Department of Geriatrics and Musculoskeletal Sciences, E.O. Galliera Hospital, Genova, Italy (4)Unit of Endocrinology & Centre of Excellence for Biomedical Research, Department of Internal Medicine and Medical Specialties, IRCCS-AOU San Martino-IST, University of Genova, Genova, Italy
|
Title: | |
Source: | Clinical Endocrinology. 79(4):457-463, October 2013.
|
Abstract: | Summary: The interplay between vitamin D and IGF-I is complex and occurs at both endocrine and paracrine/autocrine levels. Vitamin D has been shown to increase circulating IGF-I and IGFBP-3, with the consistent finding of a positive correlation between vitamin D and IGF-I serum values in population-based cohorts of healthy subjects. The modulation of IGF-I and IGFBP-3 concentrations by vitamin D may impact recombinant human (rh) GH dosing for the treatment of GHD. It might also underlie some of the extra-skeletal beneficial effects ascribed to vitamin D. On the other hand, IGF-I stimulates renal production of 1,25-dihydroxyvitamin D, which increases calcium and phosphate availability in the body and suppresses PTH secretion. This effect is responsible for an altered calcium-phosphate balance in uncontrolled acromegaly and might also account for the improvement in bone metabolism associated with rhGH treatment in patients with GHD. Data on the paracrine/autocrine vitamin D-IGF-I interactions are abundant, but mostly not linked to one another. As a result, it is not possible to draw a comprehensive picture of the physiological and/or pathological interrelations between vitamin D, IGF-I and IGF-binding proteins (IGFBP) in different tissues. A potential role of vitamin D action is related to its association with carcinogenesis, a paradigm being breast cancer. Current evidence indicates that, in breast tumours, vitamin D modulates the IGF-I/IGFBP ratio to decrease proliferation and increase apoptosis.
Copyright (C) 2013 Blackwell Publishing Ltd.
|
References: | 1. Verstuyf, A., Carmeliet, G., Bouillon, R. et al. (2010) Vitamin D: a pleiotropic hormone. Kidney International, 78, 140-145.
2. Heaney, R.P. (2008) Vitamin D in health and disease. Clinical Journal of American Society of Nephrology, 3, 1535-1541.
3. Norman, A.W. (2008) From vitamin D to hormone D: fundamentals of the vitamin D endocrine system essential for good health. American Journal of Clinical Nutrition, 88, 491S-499S.
4. Henry, H.L. (2011) Regulation of vitamin D metabolism. Best Practice & Research Clinical Endocrinology & Metabolism, 25, 531-541.
5. Norman, A.W. (2006) Minireview: vitamin D receptor: new assignments for an already busy receptor. Endocrinology, 147, 5542-5548.
6. Menegaz, D., Barrientos-Duran, A., Kline, A. et al. (2010) 1alpha,25(OH)2-Vitamin D3 stimulation of secretion via chloride channel activation in Sertoli cells. Journal of Steroid Biochemistry and Molecular Biology, 119, 127-134.
7. Donate-Correa, J., Muros-de-Fuentes, M., Mora-Fernandez, C. et al. (2012) FGF23/Klotho axis: phosphorus, mineral metabolism and beyond. Cytokine & Growth Factor Reviews, 23, 37-46.
8. Zehnder, D., Bland, R., Williams, M.C. et al. (2001) Extrarenal expression of 25-hydroxyvitamin d(3)-1 alpha-hydroxylase. Journal of Clinical Endocrinology and Metabolism, 86, 888-894.
9. Liu, P.T., Stenger, S., Li, H. et al. (2006) Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science, 311, 1770-1773.
10. Lopes, N., Sousa, B., Martins, D. et al. (2010) Alterations in Vitamin D signalling and metabolic pathways in breast cancer progression: a study of VDR, CYP27B1 and CYP24A1 expression in benign and malignant breast lesions. BMC Cancer, 10, 483.
11. Jones, J.I. & Clemmons, D.R. (1995) Insulin-like growth factors and their binding proteins: biological actions. Endocrine Reviews, 16, 3-34.
12. Yakar, S., Liu, J.L., Stannard, B. et al. (1999) Normal growth and development in the absence of hepatic insulin-like growth factor I. Proceedings of the National Academy of Sciences USA, 96, 7324-7329.
13. Ohlsson, C., Mohan, S., Sjogren, K. et al. (2009) The role of liver-derived insulin-like growth factor-I. Endocrine Reviews, 30, 494-535.
14. Camacho-Hubner, C., Rose, S., Preece, M.A. et al. (2006) Pharmacokinetic studies of recombinant human insulin-like growth factor I (rhIGF-I)/rhIGF-binding protein-3 complex administered to patients with growth hormone insensitivity syndrome. Journal of Clinical Endocrinology and Metabolism, 91, 1246-1253.
15. Tang, M.S., Redfors, B., Lindbom, M. et al. (2012) Importance of circulating IGF-1 for normal cardiac morphology, function and post infarction remodeling. Growth Hormone & IGF Research, 22, 206-211.
16. Ruan, W. & Kleinberg, D.L. (1999) Insulin-like growth factor I is essential for terminal end bud formation and ductal morphogenesis during mammary development. Endocrinology, 140, 5075-5081.
17. Gomez, J.M., Maravall, F.J., Gomez, N. et al. (2004) Relationship between 25-(OH) D3, the IGF-I system, leptin, anthropometric and body composition variables in a healthy, randomly selected population. Hormone and Metabolic Research, 36, 48-53.
18. Forouhi, N.G., Luan, J., Cooper, A. et al. (2008) Baseline serum 25-hydroxy vitamin d is predictive of future glycemic status and insulin resistance: the Medical Research Council Ely Prospective Study 1990-2000. Diabetes, 57, 2619-2625.
19. Hypponen, E., Boucher, B.J., Berry, D.J. et al. (2008) 25-hydroxyvitamin D, IGF-1, and metabolic syndrome at 45 years of age: a cross-sectional study in the 1958 British Birth Cohort. Diabetes, 57, 298-305.
20. Bogazzi, F., Rossi, G., Lombardi, M. et al. (2011) Vitamin D status may contribute to serum insulin-like growth factor I concentrations in healthy subjects. Journal of Endocrinological Investigation, 34, e200-e203.
21. Bereket, A., Cesur, Y., Ozkan, B. et al. (2010) Circulating insulin-like growth factor binding protein-4 (IGFBP-4) is not regulated by parathyroid hormone and vitamin D in vivo: evidence from children with rickets. Journal of Clinical Research in Pediatric Endocrinology, 2, 17-20.
22. Soliman, A.T., Al Khalaf, F., Alhemaidi, N. et al. (2008) Linear growth in relation to the circulating concentrations of insulin-like growth factor I, parathyroid hormone, and 25-hydroxy vitamin D in children with nutritional rickets before and after treatment: endocrine adaptation to vitamin D deficiency. Metabolism, 57, 95-102.
23. Song, Y., Kato, S. & Fleet, J.C. (2003) Vitamin D receptor (VDR) knockout mice reveal VDR-independent regulation of intestinal calcium absorption and ECaC2 and calbindin D9k mRNA. Journal of Nutrition, 133, 374-380.
24. Marcus, R., Butterfield, G., Holloway, L. et al. (1990) Effects of short term administration of recombinant human growth hormone to elderly people. Journal of Clinical Endocrinology and Metabolism, 70, 519-527.
25. Bianda, T., Hussain, M.A., Glatz, Y. et al. (1997) Effects of short-term insulin-like growth factor-I or growth hormone treatment on bone turnover, renal phosphate reabsorption and 1,25 dihydroxyvitamin D3 production in healthy man. Journal of Internal Medicine, 241, 143-150.
26. Gascon-Barre, M., Demers, C., Mirshahi, A. et al. (2003) The normal liver harbors the vitamin D nuclear receptor in nonparenchymal and biliary epithelial cells. Hepatology, 37, 1034-1042.
27. Ding, N., Yu, R.T., Subramaniam, N. et al. (2013) A Vitamin D Receptor/SMAD Genomic Circuit Gates Hepatic Fibrotic Response. Cell, 153, 601-613.
28. Zimmermann, E.M., Li, L., Hoyt, E.C. et al. (2000) Cell-specific localization of insulin-like growth factor binding protein mRNAs in rat liver. American Journal of Physiology Gastrointestinal and Liver Physiology, 278, G447-G457.
29. Liao, L., Chen, X., Wang, S. et al. (2008) Steroid receptor coactivator 3 maintains circulating insulin-like growth factor I (IGF-I) by controlling IGF-binding protein 3 expression. Molecular and Cellular Biology, 28, 2460-2469.
30. Perez-Fernandez, R., Alonso, M., Segura, C. et al. (1997) Vitamin D receptor gene expression in human pituitary gland. Life Sciences, 60, 35-42.
31. d'Emden, M.C. & Wark, J.D. (1991) Culture requirements for optimal expression of 1 alpha, 25-dihydroxyvitamin D3-enhanced thyrotropin secretion. In vitro Cellular & Developmental Biology, 27A, 197-204.
32. Cecconi, E., Gasperi, M., Genovesi, M. et al. (2005) Growth hormone secretion in primary and secondary hyperparathyroidism. Journal of Endocrinological Investigation, 28, 113-116.
33. Crowe, F.L., Key, T.J., Allen, N.E. et al. (2009) The association between diet and serum concentrations of IGF-I, IGFBP-1, IGFBP-2, and IGFBP-3 in the European Prospective Investigation into Cancer and Nutrition. Cancer Epidemiology Biomarkers & Prevention, 18, 1333-1340.
34. Araya, Z., Tang, W. & Wikvall, K. (2003) Hormonal regulation of the human sterol 27-hydroxylase gene CYP27A1. The Biochemical Journal, 372, 529-534.
35. Amato, G., Izzo, G., La Montagna, G. et al. (1996) Low dose recombinant human growth hormone normalizes bone metabolism and cortical bone density and improves trabecular bone density in growth hormone deficient adults without causing adverse effects. Clinical Endocrinology, 45, 27-32.
36. Kamenicky, P., Blanchard, A., Gauci, C. et al. (2012) Pathophysiology of renal calcium handling in acromegaly: what lies behind hypercalciuria? Journal of Clinical Endocrinology and Metabolism, 97, 2124-2133.
37. Nesbitt, T. & Drezner, M.K. (1993) Insulin-like growth factor-I regulation of renal 25-hydroxyvitamin D-1-hydroxylase activity. Endocrinology, 132, 133-138.
38. Menaa, C., Vrtovsnik, F., Friedlander, G. et al. (1995) Insulin-like growth factor I, a unique calcium-dependent stimulator of 1,25-dihydroxyvitamin D3 production. Studies in cultured mouse kidney cells. Journal of Biological Chemistry, 270, 25461-25467.
39. Wei, S., Tanaka, H. & Seino, Y. (1998) Local action of exogenous growth hormone and insulin-like growth factor-I on dihydroxyvitamin D production in LLC-PK1 cells. European Journal of Endocrinology, 139, 454-460.
40. Halhali, A., Diaz, L., Sanchez, I. et al. (1999) Effects of IGF-I on 1,25-dihydroxyvitamin D3 synthesis by human placenta in culture. Molecular Human Reproduction, 5, 771-776.
41. Halhali, A., Tovar, A.R., Torres, N. et al. (2000) Preeclampsia is associated with low circulating levels of insulin-like growth factor I and 1,25-dihydroxyvitamin D in maternal and umbilical cord compartments. Journal of Clinical Endocrinology and Metabolism, 85, 1828-1833.
42. Hollis, B.W., Johnson, D., Hulsey, T.C. et al. (2011) Vitamin D supplementation during pregnancy: double-blind, randomized clinical trial of safety and effectiveness. Journal of Bone and Mineral Research, 26, 2341-2357.
43. Bikle, D.D. (2012) Vitamin D and bone. Current Osteoporosis Reports, 10, 151-159.
44. Fernandez-Cancio, M., Audi, L., Carrascosa, A. et al. (2009) Vitamin D and growth hormone regulate growth hormone/insulin-like growth factor (GH-IGF) axis gene expression in human fetal epiphyseal chondrocytes. Growth Hormone & IGF Research, 19, 232-237.
45. Chenu, C., Valentin-Opran, A., Chavassieux, P. et al. (1990) Insulin like growth factor I hormonal regulation by growth hormone and by 1,25(OH)2D3 and activity on human osteoblast-like cells in short-term cultures. Bone, 11, 81-86.
46. Scharla, S.H., Strong, D.D., Mohan, S. et al. (1991) 1,25-Dihydroxyvitamin D3 differentially regulates the production of insulin-like growth factor I (IGF-I) and IGF-binding protein-4 in mouse osteoblasts. Endocrinology, 129, 3139-3146.
47. Zhou, S., LeBoff, M.S. & Glowacki, J. (2010) Vitamin D metabolism and action in human bone marrow stromal cells. Endocrinology, 151, 14-22.
48. Kamycheva, E., Berg, V. & Jorde, R. (2013) Insulin-like growth factor I, growth hormone, and insulin sensitivity: the effects of a one-year cholecalciferol supplementation in middle-aged overweight and obese subjects. Endocrine, 43, 412-418.
49. Carboni, J.M., Lee, A.V., Hadsell, D.L. et al. (2005) Tumor development by transgenic expression of a constitutively active insulin-like growth factor I receptor. Cancer Research, 65, 3781-3787.
50. Kleinberg, D.L., Ameri, P. & Singh, B. (2011) Pasireotide, an IGF-I action inhibitor, prevents growth hormone and estradiol-induced mammary hyperplasia. Pituitary, 14, 44-52.
51. Kleinberg, D.L., Wood, T.L., Furth, P.A. et al. (2009) Growth hormone and insulin-like growth factor-I in the transition from normal mammary development to preneoplastic mammary lesions. Endocrine Reviews, 30, 51-74.
52. Jogie-Brahim, S., Feldman, D. & Oh, Y. (2009) Unraveling insulin-like growth factor binding protein-3 actions in human disease. Endocrine Reviews, 30, 417-437.
53. Katayama, M.L., Pasini, F.S., Folgueira, M.A. et al. (2003) Molecular targets of 1,25(OH)2D3 in HC11 normal mouse mammary cell line. Journal of Steroid Biochemistry and Molecular Biology, 84, 57-69.
54. Xie, S.P., James, S.Y. & Colston, K.W. (1997) Vitamin D derivatives inhibit the mitogenic effects of IGF-I on MCF-7 human breast cancer cells. Journal of Endocrinology, 154, 495-504.
55. Colston, K.W., Perks, C.M., Xie, S.P. et al. (1998) Growth inhibition of both MCF-7 and Hs578T human breast cancer cell lines by vitamin D analogues is associated with increased expression of insulin-like growth factor binding protein-3. Journal of Molecular Endocrinology, 20, 157-162.
56. Xie, S.P., Pirianov, G. & Colston, K.W. (1999) Vitamin D analogues suppress IGF-I signalling and promote apoptosis in breast cancer cells. European Journal of Cancer, 35, 1717-1723.
57. Lee, H.J., Paul, S., Atalla, N. et al. (2008) Gemini vitamin D analogues inhibit estrogen receptor-positive and estrogen receptor-negative mammary tumorigenesis without hypercalcemic toxicity. Cancer prevention research (Philadelphia, Pa.), 1, 476-484.
58. Rozen, F., Yang, X.F., Huynh, H. et al. (1997) Antiproliferative action of vitamin D-related compounds and insulin-like growth factor-binding protein 5 accumulation. Journal of the National Cancer Institute, 89, 652-656.
59. Swami, S., Raghavachari, N., Muller, U.R. et al. (2003) Vitamin D growth inhibition of breast cancer cells: gene expression patterns assessed by cDNA microarray. Breast Cancer Research and Treatment, 80, 49-62.
60. Ruan, W., Fahlbusch, F., Clemmons, D.R. et al. (2006) SOM230 inhibits insulin-like growth factor-I action in mammary gland development by pituitary independent mechanism: mediated through somatostatin subtype receptor 3? Molecular Endocrinology, 20, 426-436.
61. Lim, E., Wu, D., Pal, B. et al. (2010) Transcriptome analyses of mouse and human mammary cell subpopulations reveal multiple conserved genes and pathways. Breast Cancer Research, 12, R21.
62. Grkovic, S., O'Reilly, V.C., Han, S. et al. (2012) IGFBP-3 binds GRP78, stimulates autophagy and promotes the survival of breast cancer cells exposed to adverse microenvironments. Oncogene, 32, 2412-2420.
63. Molitch, M.E., Clemmons, D.R., Malozowski, S. et al. (2011) Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism, 96, 1587-1609.
64. Burman, P., Johansson, A.G., Siegbahn, A. et al. (1997) Growth hormone (GH)-deficient men are more responsive to GH replacement than women. Journal of Clinical Endocrinology and Metabolism, 82, 550-555.
65. Cook, D.M., Ludlam, W.H. & Cook, M.B. (1999) Route of estrogen administration helps to determine growth hormone (GH) replacement dose in GH-deficient adults. Journal of Clinical Endocrinology and Metabolism, 84, 3956-3960.
66. Ahmad, A.M., Thomas, J., Clewes, A. et al. (2003) Effects of growth hormone replacement on parathyroid hormone sensitivity and bone mineral metabolism. Journal of Clinical Endocrinology and Metabolism, 88, 2860-2868.
67. Bianda, T., Glatz, Y., Bouillon, R. et al. (1998) Effects of short-term insulin-like growth factor-I (IGF-I) or growth hormone (GH) treatment on bone metabolism and on production of 1,25-dihydroxycholecalciferol in GH-deficient adults. Journal of Clinical Endocrinology and Metabolism, 83, 81-87.
68. Wei, S., Tanaka, H., Kubo, T. et al. (1997) Growth hormone increases serum 1,25-dihydroxyvitamin D levels and decreases 24,25-dihydroxyvitamin D levels in children with growth hormone deficiency. European Journal of Endocrinology, 136, 45-51.
69. Saggese, G., Baroncelli, G.I., Bertelloni, S. et al. (1993) Effects of long-term treatment with growth hormone on bone and mineral metabolism in children with growth hormone deficiency. Journal of Pediatrics, 122, 37-45.
70. Hansen, T.B., Brixen, K., Vahl, N. et al. (1996) Effects of 12 months of growth hormone (GH) treatment on calciotropic hormones, calcium homeostasis, and bone metabolism in adults with acquired GH deficiency: a double blind, randomized, placebo-controlled study. Journal of Clinical Endocrinology and Metabolism, 81, 3352-3359.
71. Joseph, F., Ahmad, A.M., Ul-Haq, M. et al. (2008) Effects of growth hormone administration on bone mineral metabolism, PTH sensitivity and PTH secretory rhythm in postmenopausal women with established osteoporosis. Journal of Bone and Mineral Research, 23, 721-729.
72. Parkinson, C., Kassem, M., Heickendorff, L. et al. (2003) Pegvisomant-induced serum insulin-like growth factor-I normalization in patients with acromegaly returns elevated markers of bone turnover to normal. Journal of Clinical Endocrinology and Metabolism, 88, 5650-5655.
73. Ito, N., Fukumoto, S., Taguchi, M. et al. (2007) Fibroblast growth factor (FGF)23 in patients with acromegaly. Endocrine Journal, 54, 481-484.
74. Sze, L., Bernays, R.L., Zwimpfer, C. et al. (2012) Excessively high soluble Klotho in patients with acromegaly. Journal of Internal Medicine, 272, 93-97.
75. Anderson, J.L., May, H.T., Horne, B.D. et al. (2010) Relation of vitamin D deficiency to cardiovascular risk factors, disease status, and incident events in a general healthcare population. American Journal of Cardiology, 106, 963-968.
76. Chiu, K.C., Chu, A., Go, V.L. et al. (2004) Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. American Journal of Clinical Nutrition, 79, 820-825.
77. Colao, A. (2008) The GH-IGF-I axis and the cardiovascular system: clinical implications. Clinical Endocrinology, 69, 347-358.
78. Diorio, C., Berube, S., Byrne, C. et al. (2006) Influence of insulin-like growth factors on the strength of the relation of vitamin D and calcium intakes to mammographic breast density. Cancer Research, 66, 588-597.
79. Thiebaud, D., Burckhardt, P., Costanza, M. et al. (1997) Importance of albumin, 25(OH)-vitamin D and IGFBP-3 as risk factors in elderly women and men with hip fracture. Osteoporosis International, 7, 457-462.
|
Language: | English.
|
Document Type: | Review: Review Articles/Clinical Practice Updates.
|
Journal Subset: | Clinical Medicine.
|
ISSN: | 0300-0664
|
NLM Journal Code: | dci, 0346653
|
DOI Number: | https://dx.doi.org/10.1111/cen.1...- ouverture dans une nouvelle fenêtre
|
Annotation(s) | |
|
|